

Richard Kefford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12030939/publications.pdf>

Version: 2024-02-01

77
papers

14,136
citations

147566

31
h-index

71532

76
g-index

78
all docs

78
docs citations

78
times ranked

17612
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	13.9	3,128
2	Survival in BRAF V600E-Mutant Advanced Melanoma Treated with Vemurafenib. <i>New England Journal of Medicine</i> , 2012, 366, 707-714.	13.9	1,955
3	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet, The</i> , 2014, 384, 1109-1117.	6.3	1,588
4	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	13.9	1,192
5	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	3.8	857
6	Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 616-622.	0.8	720
7	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	0.8	627
8	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109.	0.8	528
9	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2013, 31, 482-489.	0.8	439
10	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1668-1674.	0.8	360
11	Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 455-461.e1.	0.6	247
12	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600E-Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	0.8	226
13	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	3.2	222
14	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology, The</i> , 2017, 18, 1202-1210.	5.1	211
15	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. <i>Cancer</i> , 2014, 120, 1695-1701.	2.0	195
16	Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 567-574.	3.2	185
17	Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). <i>Clinical Cancer Research</i> , 2013, 19, 4868-4878.	3.2	167
18	Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3001-3001.	0.8	140

#	ARTICLE	IF	CITATIONS
19	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 358-372.	5.1	94
20	Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma. <i>Oncogenesis</i> , 2018, 7, 72.	2.1	69
21	Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. <i>Australasian Journal of Dermatology</i> , 2014, 55, 250-254.	0.4	60
22	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study. <i>Clinical Cancer Research</i> , 2016, 22, 3164-3171.	3.2	60
23	Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3005-3005.	0.8	58
24	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology, The</i> , 2014, 15, 297-304.	5.1	55
25	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 701-710.	5.1	50
26	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA9000-LBA9000.	0.8	48
27	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. <i>European Journal of Cancer</i> , 2020, 125, 114-120.	1.3	47
28	Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8510-8510.	0.8	41
29	Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 809-815.e1.	0.6	39
30	Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations. <i>Journal of Medical Genetics</i> , 2020, 57, 316-321.	1.5	33
31	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9516-9516.	0.8	32
32	Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9506-9506.	0.8	30
33	PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. <i>Immunotherapy</i> , 2016, 8, 733-746.	1.0	28
34	Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 543-543.	0.8	26
35	Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. <i>Journal of Clinical Oncology</i> , 2016, 34, e17-e20.	0.8	25
36	BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8501-8501.	0.8	24

#	ARTICLE	IF	CITATIONS
37	Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. Journal of Clinical Oncology, 2014, 32, 3006-3006.	0.8	23
38	Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 5-12.	0.7	22
39	Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.. Journal of Clinical Oncology, 2014, 32, 3015-3015.	0.8	22
40	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. Journal of Clinical Oncology, 2014, 32, LBA9000-LBA9000.	0.8	22
41	First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. Investigational New Drugs, 2021, 39, 1047-1056.	1.2	20
42	BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naïve and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM).. Journal of Clinical Oncology, 2013, 31, 9005-9005.	0.8	16
43	Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.. Journal of Clinical Oncology, 2015, 33, 3000-3000.	0.8	14
44	Updated overall survival (OS) for BR113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).. Journal of Clinical Oncology, 2014, 32, 9010-9010.	0.8	13
45	Systemic treatments for metastatic cutaneous melanoma. The Cochrane Library, 2014, , .	1.5	12
46	Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naïve (IPI-N) melanoma (MEL).. Journal of Clinical Oncology, 2014, 32, 3000-3000.	0.8	11
47	KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.. Journal of Clinical Oncology, 2017, 35, 9545-9545.	0.8	10
48	Epirubicin: A phase II study in recurrent small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 1991, 28, 220-222.	1.1	9
49	Treatment Algorithms in Stage IV Melanoma. American Journal of Therapeutics, 2015, 22, 61-67.	0.5	9
50	Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.. Journal of Clinical Oncology, 2015, 33, 9050-9050.	0.8	9
51	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.. Journal of Clinical Oncology, 2018, 36, 9590-9590.	0.8	9
52	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Targeted Oncology, 2021, 16, 47-57.	1.7	8
53	Clinical characteristics and survival of BRAF-mutant (BRAF+) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD).. Journal of Clinical Oncology, 2013, 31, 9062-9062.	0.8	8
54	Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.. Journal of Clinical Oncology, 2018, 36, 9591-9591.	0.8	8

#	ARTICLE	IF	CITATIONS
55	Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9009-9009.	0.8	7
56	Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600 mutant unresectable or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9505-9505.	0.8	7
57	<i>Pneumocystis jirovecii</i> in a patient on dose-dense chemotherapy for early breast cancer. <i>Respirology Case Reports</i> , 2019, 7, e00459.	0.3	6
58	A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9026-9026.	0.8	6
59	A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma: A subanalysis based on BRAF status.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9030-9030.	0.8	6
60	Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2021, 16, 37-46.	1.7	5
61	Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9016-9016.	0.8	5
62	Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600 mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9526-9526.	0.8	5
63	Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3068-3068.	0.8	4
64	Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9034-9034.	0.8	3
65	Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naïve patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9045-9045.	0.8	3
66	Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9077-9077.	0.8	3
67	Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9541-9541.	0.8	2
68	Analysis of circulating tumor DNA (ctDNA) in pseudoprogression in anti-PD1 treated metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9546-9546.	0.8	2
69	Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9581-9581.	0.8	2
70	Neoadjuvant systemic therapy for breast cancer: the Westmead experience. <i>ANZ Journal of Surgery</i> , 2018, 88, 640-644.	0.3	1
71	Reply to E. Hindi and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019, 37, 1356-1358.	0.8	1
72	Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9066-9066.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Patterns of acquired resistance to anti-PD-1 antibodies in patients with metastatic melanoma (MM).. Journal of Clinical Oncology, 2015, 33, e20005-e20005.	0.8	1
74	BRAF/MEK inhibition in melanoma patients with rare BRAF mutations.. Journal of Clinical Oncology, 2018, 36, 9542-9542.	0.8	1
75	Circulating tumor DNA (ctDNA) in patients (pts) with metastatic uveal melanoma (UM) treated with protein kinase C inhibitor (PKCi).. Journal of Clinical Oncology, 2020, 38, e22054-e22054.	0.8	1
76	Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma.. Journal of Clinical Oncology, 2014, 32, 9004-9004.	0.8	0
77	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutationâ€“positive melanoma with metastases to the brain (BRV116521).. Journal of Clinical Oncology, 2014, 32, TPS9112-TPS9112.	0.8	0